The investigator's brochure, explained.

What an investigator's brochure is, and why one small number can send a team through 200 pages

One brochure update, from the cut-off date to the trial site

1. The cut-off date arrivesVeltrimab's data cut-off is August 31, 2026. Whatever is final by then belongs in Edition 10.
2. Sources are gatheredFourteen documents since Edition 9: study reports, integrated analyses, nonclinical and stability reports, protocols, a study tracker.
3. Each section is updated, and each fact is followedTracked changes with a source for each. This is where a half-life gets changed in three places, or in two.
4. Owners accept, and a medical lead signsEach discipline approves its data. The medical lead approves the edition, with the meaning of the signature on record.
5. Regulators, ethics committees and sites receive itWhat that takes depends on the country and on what changed. Consent forms and manuals that quote the old value follow their own path.

Step 3 is the subject of this guide. The people, drugs, studies and figures in this example are fictional.

Why brochure updates are harder than they look: four findings that surprise newcomers

Investigator's brochure, cut-off, edition, summary of changes: the words to know

Fourteen terms are defined in the one-page summary.

The investigator's brochure template in ICH E6(R3) Appendix A: seven sections and who answers for each

In shortAppendix A of ICH E6(R3) lists a table of contents, a summary, an introduction, the product's properties, nonclinical studies, effects in humans and a closing section of data and guidance. It asks for concise, balanced, non-promotional writing, a medically qualified person in the work, and approval by the disciplines that generated the data. We found no official form or template file from ICH, FDA or the EU: sponsors build their own on this list.

If you learned this document from an older guideline, note the move. In E6(R2) the brochure was section 7.8 In E6(R3) it is Appendix A, and Appendix B is the protocol.1 The content changed less than its place in the guideline. US rules ask for a shorter list of five items: the drug substance and formulation, pharmacology and toxicology, pharmacokinetics (how the body absorbs, spreads and clears a drug), what prior human studies showed, and the risks to anticipate with precautions.9

E6(R3)'s seven brochure sections, what goes in them and who usually answers

Source: ICH E6(R3), Appendix A.1 The "who" column is our reading of common practice. E6(R3) itself says only that a medically qualified person should be involved and that "the contents of the IB should be approved by the disciplines that generated the described data".1

This guide covers the trial-data summary that a team updates each year. E6(R3) and EU rules also require brochure content beyond these seven sections, usually kept by other functions under their own procedures.1,5 That content is part of a real brochure, and this guide does not cover it.

The fictional brochure in this guide numbers those sections 1 to 6, from the summary to the guidance, and splits some into parts such as 5.1 and 5.2. Its latest update shows where a year's changes land.

Why the tone of an investigator's brochure is a rule in itself

EU rules and E6(R3) use almost the same words: the information must be "concise, simple, objective, balanced and non-promotional", so that a clinician can make an unbiased judgment of whether the trial is appropriate.1,10 An IB states the finding and the size of the effect, and avoids adjectives. A reader should be able to find a result that went badly as easily as one that went well. That is harder than it sounds in a document assembled from reports written by teams who want their study to look good.

ICH E6(R3), EU Article 55 and 21 CFR 312.55: what each one asks of a brochure update

In shortICH E6(R3), the guideline on good clinical practice (the international ethical and quality standard for running trials), sets the content and the yearly review. It took effect in the EU on July 23, 2025, and FDA published it as final guidance in September 2025. EU law repeats the yearly review in Article 55 of its Clinical Trials Regulation. US rules ask the sponsor to keep investigators informed and to report revisions in the annual report. A brochure update therefore has one content standard and several delivery routes.

What the US, the EU and the UK each ask when a brochure changes

ICH is the International Council for Harmonisation. 21 CFR is Title 21 of the US Code of Federal Regulations. CTIS is the EU's Clinical Trials Information System, the single portal for applications. We read the US, EU and UK texts above. Check your other countries with local counsel or your regulatory lead: routes differ, and this table is a map for planning.

When an annual IB update is a substantial modification, and what that does to your calendar

In shortThree questions decide what happens: did the review find anything worth changing, must investigators hear it before the edition is ready, and does the change touch benefit and risk? In the EU, the last answer decides between a filed update and a formal application with clocks of 49 to 80 days, before any completeness queries or expert consultation. The sponsor makes the call and can be corrected for getting it wrong.

How the EU sorts a new brochure version: filed or authorized

The European Commission's questions and answers document, version 7.4 of October 2026, uses the brochure as its own example. A new version "can be uploaded as an SM (e.g. with changes impacting benefit/risk in the trial) or as an art.81(9) (e.g. annual update with no significant changes on subjects safety and/or benefit/risk in the trial)". SM stands for substantial modification.

The document adds: "It is up to the sponsor to define the correct path".5 The portal cannot tell the difference between the two, and misusing the lighter route can bring corrective measures.5

Germany's Paul-Ehrlich-Institut, a national medicines authority, puts it in plain terms: an annual update "without any changes to the safety, efficacy or benefit-risk assessment" is an Article 81(9) modification, and if a group of changes grows it may become a substantial modification.15 So at kickoff a team often cannot yet name the route. A writer on the subject notes that the team may need to review the draft before it can say whether an update is substantial.7

A proposal could shorten this. The European Commission's Biotech Act proposal of December 2025 would compress substantial modification timelines from 96 days to 47, or to 33 with no request for more information, as a law firm summarized it.17 The firm does not break down its 96, which is longer than the 80 above. It is a proposal: Parliament's file read "Awaiting committee decision" on November 3, 2026.18 Plan on the current clocks.

The dates on one fictional brochure, from sponsor approval to the last country

How a changed half-life moves a contraception period: the arithmetic inside a brochure

In shortMost brochure numbers are copies: exposure, status, results. Some are derived: a period set at five half-lives, an exposure margin, a patient-year total. A copy can be searched. A derived value often cannot, because its sentence never mentions the input. This section works five of them through with the fictional case's numbers.

Worked example: from a half-life to a contraception period

A half-life is the time the body takes to clear half of what is present. After one half-life, half remains. After two, a quarter. After five, about 3%. That is why trial teams often use five half-lives as the point where a drug has mostly gone.

Edition 9 gave about 26 days. Five half-lives is 130 days, or 18.6 weeks, stated as 19. The new population analysis gives 28.1 days, so about 28. Five half-lives is 140 days, which is exactly 20 weeks. A shift of two days in a pharmacology table becomes a week of contraception for a participant, in a sentence 34 pages further on.

Real trials show the same chain. A protocol posted publicly on ClinicalTrials.gov records this amendment from June 2019: the half-life had "been re-estimated to 28 days", and "as duration of contraceptive measures is required to last for 5 half-lives", the period moved "from 3 months (12 weeks) to 5 months", with pregnancy test timing changed too.6 One value, re-estimated, reached a protocol's flow chart and its appendix.

Four more calculated values to check in every investigator's brochure

Which of twelve changed facts sits where in one fictional brochure

What may go into an IB: study reports, interim analyses, and the draft that has to wait

In shortA brochure draws on a dozen or more documents, from several systems, each with its own version. A house rule such as "cite final, approved documents only" blocks drafts well. Applied to every interim analysis it goes further than ICH E6(R3), which asks for ongoing trials' interim results where they may inform the safety evaluation. An approved interim report deserves a decision by the medical lead.

The source documents, the sections they feed and who holds them

Draft against interim: why Week 52 stays out, and when an interim result belongs

The example has a result the team would love to print. A Week 52 remission figure for ulcerative colitis exists in VLT-303 interim analysis IA-2, a planned early look at data while the trial runs. That document is a draft, dated September 14, two weeks after the cut-off, and nobody has approved it. It stays out on all three counts.

Now change the facts. Suppose an interim report is approved and final as a document. E6(R3) asks that, where possible, the brochure give "a summary of each completed clinical trial and ongoing trials where interim results are available that may inform the safety evaluation".1 A blanket house rule against interim data would conflict with that request.

The clause speaks of the safety evaluation, so it reaches an efficacy figure (how well the drug works) such as remission less directly. The test therefore has three parts: is the document approved, is it inside the cut-off, and does the result bear on how the person giving the drug should judge it, above all on its safety?

IB and informed consent consistency: what happens when a brochure fact also sits in other trial documents

In shortConsent forms, protocols and pharmacy manuals quote brochure facts, each with its own owner, version and review. A brochure change can require a new consent form, and revised consent materials need ethics committee approval before use. Reviewers compare these documents, and inconsistency is a recognized cause of delay. We found no public measure of how many teams keep a list of which document quotes which fact.

Consent forms matter most, because participants read them. ICH E6(R3) says participants should be told in a timely manner of new information relevant to their willingness to continue, that such information should be assessed to decide whether they need to consent again (re-consent), and that revised materials "should receive the IRB/IEC's approval/favourable opinion in advance of use".1 IRB and IEC, the institutional review board and the independent ethics committee, are two names for the independent panels that review a trial's ethics.

US rules require consent to state that significant new findings will be provided to participants where they may relate to willingness to continue, and, where appropriate, to mention risks to an embryo or fetus.20

Review boards read across documents. An NIH tip sheet for review board members says to confirm that "the ICD matches the protocol and, when applicable, the Investigational Brochure (IB) or package insert", ICD being the informed consent document.21 A review board services company writes that "one of the most common reasons for delay in IRB approval is inconsistency between the protocol and the informed consent form".22 We found no public count of how often a brochure change is the cause.

Three kinds of document that quote a changed brochure fact, in the example

Fictional sample passages. E6(R3) lists instructions such as a pharmacy manual among essential records when they are kept outside the protocol or brochure.1

Common investigator's brochure errors: stale counts, old statuses, missed derived values and thin evidence

In shortErrors repeat: counts from the old cut-off, a study still called ongoing, one number rounded two ways, a period that no longer follows from its input. Inspectors have found a brochure whose count disagreed with a study report. One large study found the preclinical evidence in brochures too thin to judge. The UK inspection reports we read do not isolate brochure findings as a category.

What UK inspectors reported about one brochure's numbers

The UK regulator's GCP inspection reports describe what it found, without naming companies. One case bears directly on reconciling counts.

It was part of a wider finding at one company, reported in MHRA's yearly metrics. It shows what can happen and does not show how often. These reports carry other brochure findings on subjects this guide does not cover. We could not read a primary FDA warning letter on a stale brochure, so none is cited.

What a study of 109 investigator's brochures found about the evidence inside them

Researchers read 109 brochures submitted to three German review boards, holding 708 preclinical efficacy studies, meaning lab and animal work suggesting the drug might work. Most of those studies could not support the judgment the brochure exists for.24 The sample was not random, and it covers only this kind of data and that period. The finding still points somewhere useful: a brochure rewards a reader who can trace a claim to its source, and these brochures rarely allowed it.

Eight brochure errors and why each one happens

What a stale or inconsistent brochure risks for participants, sites, approvals and inspections

In shortFour groups carry the risk: a participant who gets out-of-date advice, a doctor deciding with old numbers, a study team waiting on a second filing, and a sponsor explaining records to an inspector. Costs vary too much for a single figure. Rank your own by what the error can do, and by how late you would find it.

What AI can do in investigator's brochure updates, and what FDA, EMA and the EU expect

In shortWe found no published study of AI drafting an investigator's brochure. Neighboring studies show models write fluently and invent facts unless made to work from source documents, which is called grounding, and improve when people check the structure. Regulators ask the sponsor to answer for the tool. FDA's January 2025 draft sets aside drafting that does not affect patient safety, drug quality or study reliability. Draft EU GMP Annex 22 concerns manufacturing and does not govern a brochure.

What automation changes in a brochure update, and what stays with people

What three neighboring studies measured when AI wrote clinical documents

These papers are about other documents. They suggest three things for a brochure: base every sentence on a named source, treat tables as data, and put a person where the structure is checked. None measures the failure this guide spends the most time on, a fact that reaches some places and misses others.

What regulators say that applies to an AI-assisted brochure

How many brochures exist: the closest public counts of INDs, pipelines and EU modifications

In shortNo one counts investigator's brochures. Three nearby figures give a sense of scale: about 15,000 INDs, the applications to test a drug in people, with activity at FDA's drug center in 2025, about 23,000 drugs in development worldwide, and about two substantial modifications per initial application so far in the EU. No public figure exists for the medical writing spent on brochures, so we print none.

The trend to watch is structure. The ICH M11 protocol template, E6(R3)'s record-keeping expectations and EU portal rules all push clinical documents toward versions and data that can be compared. We know of no equivalent structured template for the brochure from ICH. A brochure kept as a long Word file holds facts that have to be found by reading.

Who runs the annual IB update today: from cut-off to submission, by hand

In shortA clinical scientist or medical writer owns the update, and four or five specialists own its sections. The work runs through shared folders, spreadsheets and comments. The split of days below is one estimate, since no public figure exists. Time yours once and you will hold a number nobody publishes.

The people an investigator's brochure passes through before it is signed

Where about five weeks of working days might go in one by-hand brochure update

Three facts sit behind that estimate, and each can be checked in your team within a week: how many systems hold your sources, how long it takes to recount exposure, and whether anyone has a list of documents that quote the brochure.

In house, outsourced, document software or AI-assisted: four ways to run a brochure update

From Edition 9 to a signed Edition 10: twelve facts, 22 statements and 8 places in other documents

In shortThis is the example from the top of the page, inside the product. Dr. Lena Ortiz, the clinical scientist who owns the brochure, opens the edition's facts side by side. She follows exposure into a consent form, sees a draft Week 52 result kept out, traces the half-life through 3 statements and 2 consent forms, and sends the edition to Dr. Maya Chen, the medical lead, who signs with the counts in her reason.

1

Last edition's facts beside the proposed ones

It is October 7, 2026, 23 days before Edition 10 is due. Overnight, sources were collected and sections drafted. Lena's first screen holds no document at all. It lists twelve facts, with Edition 9 on the left and the proposed value on the right, and a switch on each row.

The panel on the right counts the impact: 19 statements updated in the brochure, 6 places in other documents, and 3 statements still behind the newest approved source. The half-life row is hatched and switched off. It waits for her, because it moves another section.

2

Exposure: two statements, and a consent form that says "about 1,200"

Lena clicks Participants exposed. It moves from 1,212 to 1,846, from the integrated exposure report at the cut-off. Where it appears lists the Summary on page 7 and Table 5-4 on page 66, with what each would say.

Below them sits a line no search of the brochure would find: section 2 of the extension study's consent form, version 3, still says "About 1,200 people have received veltrimab so far". It is marked to amend, and its owner will be told.

3

Week 52 remission stays out, with its check named

Lena types "Week 52 remission" and clicks Trace. The result exists only in VLT-303 interim analysis IA-2, a draft dated September 14, 2026, which nobody has approved. The tracer keeps it out and names the rule: final, approved sources only.

That is the sample sponsor's house rule, and a sensible one for a draft. Part A explains why an approved interim result needs a different conversation: E6(R3) asks for interim results that may inform the safety evaluation.1 Bring that case to your medical lead, and test how any tool handles it.

4

The half-life goes in, and the counters move to 22 and 8

Now Lena traces "Half-life". The 2026 population analysis of 1,410 participants gives a typical value of 28.1 days, from a final report, so the row switches on. Statements updated rise to 22, places in other documents to 8, and statements behind the newest approved source fall from 3 to 0.

Nothing has changed at any site yet. The screen says so: in this sample, investigators keep Edition 9 until Edition 10 is approved in all 14 countries. That is this fictional sponsor's rollout choice. Part A sets out what FDA, the EU and the UK ask.

5

Every place the half-life lives, and the drafted summary entry

The panel lists page 7, page 58 and page 92, where the contraception period becomes 20 weeks. Two consent forms, VLT-301 version 4 and the extension's version 3, still say "for 19 weeks after your last dose".

The draft entry for the summary of changes fills in with the old value, the new one, the report's name and the reason. It notes that protocol VLT-302 amendment 3 already says 20 weeks, so the team knows part of the program moved first.

6

Dr. Maya Chen signs, with the meaning and a reason

Lena sends Edition 10 for approval. Maya's signature carries its meaning, "I approve Investigator's Brochure Edition 10 for Veltrimab", and a reason filled from the counts: 12 facts changed, 22 statements updated, every one cited, 8 places flagged to their owners. She enters her password and signs.

The row at the foot now reads Approved by Dr. Maya Chen, Oct 7, with a link to the draft at Section 6. In this sample the medical lead approves the proposed facts first, and section owners then decide each change's wording in the draft. Set the order your procedure requires.

Select any screen to open it larger. The 22 and the 8 are what this sample shows, and your own brochures will differ.

Tracked changes with sources, the brochure shelf, the fact check and your update settings

In shortAround the side-by-side view sit the screens a clinical team uses all year: a draft with each change beside its source passage, a generated summary of changes, the overnight run, a shelf of every brochure by due date, a fact check with evidence for each finding, a dashboard, and settings that hold your cycle, checks and section owners.

Tracked changes beside the passage they came from

The brochure shelf: eleven investigator's brochures, each on its own clock

The same check on a second and third product: a dose and a food effect

The method holds across different kinds of medicine. NWB-2290, a fictional antibody-drug conjugate, has a recommended Phase 2 dose of 4.8 mg/kg ready, while protocol ADC-201 still allows up to 6.0 mg/kg. Dravenzo, a fictional oral tablet, must now be taken with food after a 38% food effect, while protocol CRV-202 still says "with or without food".

The fact check: seven findings for Edition 10, each with its evidence

The update dashboard and the settings that a clinical team owns

Six brochure agents, the section owners who decide and the medical lead who approves

In shortSix specialist agents collect, draft, trace, find, check and summarize. None of them accepts a change, edits another team's document or signs. Section owners decide their sections, the IB owner decides facts that cross sections, and the medical lead approves the edition.

What each brochure agent does, and where it stops

Who accepts a change, who decides a cross-section fact and who signs an edition

The people in the Veltrimab sample, in their own words

From last edition and new reports to a cited draft and flagged consent forms

In shortThe solution reads the documents an update already depends on, and returns the facts side by side, the change impact, a tracked-changes draft, a summary of changes and an approved edition with its audit trail. Its design target is three to five days from cut-off to a full cited draft, against an estimate of about five weeks by hand. Measure both on your own brochures.

The systems an investigator's brochure update connects to

Audit trail, signatures and credentials a quality team will ask about

Each agent run, change decision, fact check, owner notification and signature is recorded with who, what and when, and the trail can be exported. Your brochures stay in your environment, and models do not train on them. The signature shows signer, time and meaning, which is what 21 CFR 11.50 looks for in a signed record.33 These are controls that support your compliance with Part 11, and validating them for your use stays with you.

Botminds' information security is managed to ISO 27001 and audited under SOC 2 Type II. No product can be certified for good clinical practice or Part 11, and we make no such claim. The solution runs at enterprise scale across a portfolio of brochures, with roles, maker-checker approvals, service levels and administration your IT team can own.

What a brochure mismatch and a slow update cost a clinical program

In shortNobody publishes a cost per brochure update or per missed fact. Start from your own hours. Published figures frame the scale of what a late mismatch can trigger: a second filing, a protocol amendment and running a trial while it waits. Use them as context, and leave them out of your business case unless you can tie them to your own cases.

Seven brochure costs to find in a week, starting with your last edition

What brochure cost totals leave out: a site's trust, an owner's judgment and a reason nobody remembers

What faster IB updates return: team days released, plus rework you no longer pay for

In shortPut in your own numbers. The calculator values team days released on each update and, separately, the rework avoided when a mismatch is found before submission. Every default is illustrative or the solution's estimate, since no public benchmark exists. The hourly cost is an illustrative loaded cost, meaning pay plus overhead: replace it with your own.

Collecting, tracing, drafting, late finds: where brochure automation saves

Brochures a year, team days and late mismatches on your own figures

How ready your clinical team is: brochures, sources, owners and sign-off

In shortPick the answer closest to your team today. Eight questions score 0 to 2, and the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

Twelve questions for any IB authoring software vendor, us included

In shortAlmost every tool demonstrates well on a clean sample. These questions test what a demonstration hides: whether it finds derived values, whether a number keeps its source, how it treats interim results, whether it reaches consent forms, and who can approve what. Ask us too.

Testing brochure software in ten weeks: one signed edition, planted errors, one live update

In shortStart with an edition you already signed, because you know what changed. Plant errors to measure the checks, then run one live update in parallel with your usual process. Decide on three numbers: days to a cited draft, planted mismatches found, and other documents found that your team had missed.

Days to a cited draft, planted mismatches found and quoting documents missed

Investigator's brochure questions answered: contents, updates, substantial changes and AI

In shortThe questions clinical teams and buyers search for most, each answered on its own.